Janus kinases: components of multiple signaling pathways
- PMID: 11114747
- DOI: 10.1038/sj.onc.1203925
Janus kinases: components of multiple signaling pathways
Abstract
Cytoplasmic Janus protein tyrosine kinases (JAKs) are crucial components of diverse signal transduction pathways that govern cellular survival, proliferation, differentiation and apoptosis. Evidence to date, indicates that JAK kinase function may integrate components of diverse signaling cascades. While it is likely that activation of STAT proteins may be an important function attributed to the JAK kinases, it is certainly not the only function performed by this key family of cytoplasmic tyrosine kinases. Emerging evidence indicates that phosphorylation of cytokine and growth factor receptors may be the primary functional attribute of JAK kinases. The JAK-triggered receptor phosphorylation can potentially be a rate-limiting event for a successful culmination of downstream signaling events. In support of this hypothesis, it has been found that JAK kinase function is required for optimal activation of the Src-kinase cascade, the Ras-MAP kinase pathway, the PI3K-AKT pathway and STAT signaling following the interaction of cytokine/interferon receptors with their ligands. Aberrations in JAK kinase activity, that may lead to derailment of one or more of the above mentioned pathways could disrupt normal cellular responses and result in disease states. Thus, over-activation of JAK kinases has been implicated in tumorigenesis. In contrast, loss of JAK kinase function has been found to result in disease states such as severe-combined immunodeficiency. In summary, optimal JAK kinase activity is a critical determinant of normal transmission of cytokine and growth factor signals.
Similar articles
-
IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled.Oncogene. 2000 May 15;19(21):2532-47. doi: 10.1038/sj.onc.1203594. Oncogene. 2000. PMID: 10851052 Review.
-
JAKs, STATs and Src kinases in hematopoiesis.Oncogene. 2002 May 13;21(21):3334-58. doi: 10.1038/sj.onc.1205398. Oncogene. 2002. PMID: 12032773 Review.
-
Negative regulation of Janus kinases.Cell Biochem Biophys. 2001;34(1):17-59. doi: 10.1385/CBB:34:1:17. Cell Biochem Biophys. 2001. PMID: 11394440 Review.
-
The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.Oncogene. 2000 Sep 28;19(41):4795-801. doi: 10.1038/sj.onc.1203829. Oncogene. 2000. PMID: 11032030
-
The Janus protein tyrosine kinases in hematopoietic cytokine signaling.Semin Immunol. 1995 Aug;7(4):247-54. doi: 10.1006/smim.1995.0029. Semin Immunol. 1995. PMID: 8520029 Review.
Cited by
-
Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling.Mol Cell Biochem. 2013 Sep;381(1-2):273-82. doi: 10.1007/s11010-013-1711-x. Epub 2013 Jun 6. Mol Cell Biochem. 2013. PMID: 23740516
-
Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.Int J Cancer. 2013 Feb 1;132(3):509-20. doi: 10.1002/ijc.27690. Epub 2012 Jul 9. Int J Cancer. 2013. PMID: 22729867 Free PMC article.
-
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.Blood. 2005 Aug 1;106(3):996-1002. doi: 10.1182/blood-2005-02-0707. Epub 2005 Apr 14. Blood. 2005. PMID: 15831699 Free PMC article.
-
Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.Clin Cancer Res. 2011 May 1;17(9):2668-78. doi: 10.1158/1078-0432.CCR-10-2114. Epub 2011 Jan 19. Clin Cancer Res. 2011. PMID: 21248298 Free PMC article.
-
Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.J Hematol Oncol. 2018 Jan 31;11(1):14. doi: 10.1186/s13045-017-0551-7. J Hematol Oncol. 2018. PMID: 29386069 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous